Telo Genomics Corp. (TDSGF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.82 Million CAD | -33.66% |
| 2022 | -2.11 Million CAD | -97.25% |
| 2021 | -1.06 Million CAD | 13.83% |
| 2020 | -1.24 Million CAD | -15.59% |
| 2019 | -1.07 Million CAD | 77.12% |
| 2018 | -4.69 Million CAD | 52.64% |
| 2017 | -9.91 Million CAD | -14051.29% |
| 2016 | -70.05 Thousand CAD | 35.57% |
| 2015 | -108.73 Thousand CAD | -192.36% |
| 2014 | -37.19 Thousand CAD | 68.54% |
| 2013 | -118.22 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -606.06 Thousand CAD | 27.43% |
| 2024 Q1 | -672.54 Thousand CAD | 21.33% |
| 2024 Q2 | -835.14 Thousand CAD | -24.18% |
| 2023 Q1 | -615.8 Thousand CAD | 5.73% |
| 2023 FY | -2.82 Million CAD | -33.66% |
| 2023 Q2 | -639.21 Thousand CAD | -3.8% |
| 2023 Q3 | -710.88 Thousand CAD | -11.21% |
| 2023 Q4 | -854.87 Thousand CAD | -20.25% |
| 2022 Q2 | -463.29 Thousand CAD | 3.27% |
| 2022 Q1 | -478.94 Thousand CAD | -37.16% |
| 2022 FY | -2.11 Million CAD | -97.25% |
| 2022 Q4 | -653.23 Thousand CAD | -26.85% |
| 2022 Q3 | -514.98 Thousand CAD | -11.16% |
| 2021 FY | -1.06 Million CAD | 13.83% |
| 2021 Q3 | -309.6 Thousand CAD | -12.95% |
| 2021 Q2 | -274.11 Thousand CAD | -99.99% |
| 2021 Q1 | -137.06 Thousand CAD | 58.93% |
| 2021 Q4 | -349.18 Thousand CAD | -12.78% |
| 2020 FY | -1.24 Million CAD | -15.59% |
| 2020 Q1 | -138.64 Thousand CAD | 32.19% |
| 2020 Q2 | -561.04 Thousand CAD | -304.67% |
| 2020 Q3 | -321.42 Thousand CAD | 42.71% |
| 2020 Q4 | -333.69 Thousand CAD | -3.82% |
| 2019 Q2 | -176.02 Thousand CAD | 69.61% |
| 2019 FY | -1.07 Million CAD | 77.12% |
| 2019 Q4 | -204.46 Thousand CAD | -78.66% |
| 2019 Q3 | -114.44 Thousand CAD | 34.98% |
| 2019 Q1 | -579.25 Thousand CAD | 49.89% |
| 2018 Q2 | -1.55 Million CAD | -45.52% |
| 2018 FY | -4.69 Million CAD | 52.64% |
| 2018 Q4 | -1.15 Million CAD | -25.55% |
| 2018 Q3 | -920.75 Thousand CAD | 40.66% |
| 2018 Q1 | -1.06 Million CAD | 61.44% |
| 2017 FY | -9.91 Million CAD | -14051.29% |
| 2017 Q3 | -2.17 Million CAD | -35.18% |
| 2017 Q1 | -3.36 Million CAD | -20977.03% |
| 2017 Q2 | -1.6 Million CAD | 52.3% |
| 2017 Q4 | -2.76 Million CAD | -27.31% |
| 2016 Q3 | -42.73 Thousand CAD | 30.11% |
| 2016 Q2 | -61.14 Thousand CAD | -1826.14% |
| 2016 Q1 | 3542.00 CAD | 150.32% |
| 2016 FY | -70.05 Thousand CAD | 35.57% |
| 2016 Q4 | -15.97 Thousand CAD | 62.61% |
| 2015 FY | -108.73 Thousand CAD | -192.36% |
| 2015 Q4 | -7039.00 CAD | -29.97% |
| 2015 Q3 | -5416.00 CAD | 67.12% |
| 2015 Q2 | -16.47 Thousand CAD | -50.93% |
| 2015 Q1 | -10.91 Thousand CAD | 57.67% |
| 2014 FY | -37.19 Thousand CAD | 68.54% |
| 2014 Q1 | -2315.00 CAD | 77.52% |
| 2014 Q2 | -18.92 Thousand CAD | -717.54% |
| 2014 Q3 | -55.57 Thousand CAD | -193.62% |
| 2014 Q4 | -25.77 Thousand CAD | 53.62% |
| 2013 Q2 | -12.52 Thousand CAD | -106.77% |
| 2013 Q4 | -10.3 Thousand CAD | -82.3% |
| 2013 FY | -118.22 Thousand CAD | 0.0% |
| 2013 Q3 | -5650.00 CAD | 54.89% |
| 2013 Q1 | -6058.00 CAD | 47.36% |
| 2012 Q4 | -11.5 Thousand CAD | 86.94% |
| 2012 Q3 | -88.13 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.41 Million USD | -100.055% |
| Arrayit Corporation | -3.31 Million USD | 14.924% |
| Atlantic International Corp. | -5.62 Million USD | 49.876% |
| Biocept, Inc. | -32.08 Million USD | 91.209% |
| Bioqual, Inc. | 483.48 Thousand USD | 683.43% |
| CardioGenics Holdings Inc | -1.91 Million USD | -47.197% |
| DermTech, Inc. | -100.88 Million USD | 97.204% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion USD | 100.139% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 86.938% |
| iMD Companies, Inc. | -200.63 Thousand USD | -1305.915% |
| IDenta Corp. | 14.64 Thousand USD | 19362.305% |
| Interpace Biosciences, Inc. | 802 Thousand USD | 451.717% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | 7390.889% |
| InVitro International | 1553.00 USD | 181733.741% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 67.17% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -4754.027% |
| Medical Imaging Corp. | -3.02 Million USD | 6.69% |
| NovelStem International Corp. | -4.18 Million USD | 32.635% |
| Optigenex Inc. | -2.89 Million USD | 2.657% |
| PharmChem, Inc. | 845.1 Thousand USD | 433.779% |
| Proteome Sciences plc | -2.44 Million USD | -15.463% |
| Response Genetics, Inc | -20.18 Million USD | 86.025% |
| Rennova Health, Inc. | -3.29 Million USD | 14.342% |
| RushNet, Inc. | -607.02 Thousand USD | -364.686% |
| ScreenPro Security Inc. | -2.24 Million USD | -25.436% |
| Stella Diagnostics Inc. | -5.7 Million USD | 50.577% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 75.29% |
| Todos Medical Ltd. | -24.99 Million USD | 88.714% |